Last reviewed 2026-04-20 · How we verify

MM-II dose I

At a glance

Approved indications

No approved indications tracked.

Common side effects

• COVID-19
• Nasopharyngitis
• Hypertension
• Arthralgia
• Anaemia
• Urinary tract infection
• Influenza like illness
• Leukopenia
• Pain in extremity
• Back pain
• Ligament sprain
• Joint injury

Key clinical trials

• A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM) (PHASE1)
• Ixazomib + Pomalidomide + Dexamethasone In MM (PHASE1, PHASE2)
• Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases (PHASE1, PHASE2)
• Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma (PHASE2)
• Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (PHASE3)
• A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People (PHASE1, PHASE2)
• Ultrasound IPP to Predict Response to Medical Therapy in LUTS/BPH
• Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.